These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 14706566)

  • 1. VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice.
    Moody TW; Dudek J; Zakowicz H; Walters J; Jensen RT; Petricoin E; Couldrey C; Green JE
    Life Sci; 2004 Jan; 74(11):1345-57. PubMed ID: 14706566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasoactive intestinal polypeptide VPAC1 and VPAC2 receptor chimeras identify domains responsible for the specificity of ligand binding and activation.
    Juarranz MG; Van Rampelbergh J; Gourlet P; De Neef P; Cnudde J; Robberecht P; Waelbroeck M
    Eur J Biochem; 1999 Oct; 265(1):449-56. PubMed ID: 10491203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
    Moody TW; Jensen RT; Fridkin M; Gozes I
    J Mol Neurosci; 2002; 18(1-2):29-35. PubMed ID: 11931347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
    Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
    J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines.
    Zia H; Leyton J; Casibang M; Hau V; Brenneman D; Fridkin M; Gozes I; Moody TW
    Life Sci; 2000; 66(5):379-87. PubMed ID: 10670826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.
    García-Fernández MO; Collado B; Bodega G; Cortés J; Ruíz-Villaespesa A; Carmena MJ; Prieto JC
    Gynecol Endocrinol; 2005 Jun; 20(6):327-33. PubMed ID: 16019382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasoactive intestinal peptide (VIP) stimulates cortisol secretion from the H295 human adrenocortical tumour cell line via VPAC1 receptors.
    Nicol MR; Cobb VJ; Williams BC; Morley SD; Walker SW; Mason JI
    J Mol Endocrinol; 2004 Jun; 32(3):869-77. PubMed ID: 15171718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells.
    Sharma A; Walters J; Gozes Y; Fridkin M; Brenneman D; Gozes I; Moody TW
    J Mol Neurosci; 2001 Dec; 17(3):331-9. PubMed ID: 11859929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for the involvement of VPAC1 and VPAC2 receptors in pressure-induced vasodilatation in rodents.
    Fizanne L; Sigaudo-Roussel D; Saumet JL; Fromy B
    J Physiol; 2004 Jan; 554(Pt 2):519-28. PubMed ID: 14578481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro properties of a high affinity selective antagonist of the VIP1 receptor.
    Gourlet P; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
    Peptides; 1997; 18(10):1555-60. PubMed ID: 9437716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
    Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
    Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
    Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
    Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
    Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
    J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
    Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
    Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation.
    St Hilaire RC; Murthy SN; Kadowitz PJ; Jeter JR
    Peptides; 2010 Aug; 31(8):1517-22. PubMed ID: 20452385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasoactive intestinal polypeptide receptor VPAC(1) subtype is predominant in rat prostate membranes.
    Juarranz MG; De Neef P; Robberecht P
    Prostate; 1999 Sep; 41(1):1-6. PubMed ID: 10440869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor.
    Moreno D; Gourlet P; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
    Peptides; 2000 Oct; 21(10):1543-9. PubMed ID: 11068102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
    Cunha-Reis D; Ribeiro JA; Sebastião AM
    Brain Res; 2005 Jul; 1049(1):52-60. PubMed ID: 15935995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasoactive intestinal peptide (VIP) inhibits the proliferation of bone marrow progenitors through the VPAC1 receptor.
    Rameshwar P; Gascon P; Oh HS; Denny TN; Zhu G; Ganea D
    Exp Hematol; 2002 Sep; 30(9):1001-9. PubMed ID: 12225791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.